PCSK9 and cardiovascular disorder: As such, concentrating this Review’s discussion on published PCSK9 editing studies provides a comprehensive overview of progress in the therapeutic genome editing field and illustrates the key choices that must be made in designing genome-editing therapies, with no other genes (whether involved in cardiovascular diseases or in other diseases) having nearly the same breadth of data at the present time.